Woodline Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-450,199
| Closed | -$3.39M | – | 915 |
|
|
2024
Q4 | $3.39M | Buy |
+450,199
| New | +$3.39M | 0.02% | 563 |
|
|
2023
Q2 | – | Sell |
-701,580
| Closed | -$5.85M | – | 640 |
|
|
2023
Q1 | $5.85M | Sell |
701,580
-1,369,403
| -66% | -$11.4M | 0.08% | 269 |
|
|
2022
Q4 | $23.8M | Buy |
+2,070,983
| New | +$23.8M | 0.32% | 82 |
|
|
2021
Q1 | – | Sell |
-155,844
| Closed | -$1.16M | – | 431 |
|
|
2020
Q4 | $1.16M | Sell |
155,844
-712,864
| -82% | -$5.31M | 0.03% | 207 |
|
|
2020
Q3 | $2.98M | Sell |
868,708
-722,133
| -45% | -$2.48M | 0.1% | 157 |
|
|
2020
Q2 | $7.58M | Buy |
1,590,841
+336,314
| +27% | +$1.6M | 0.3% | 84 |
|
|
2020
Q1 | $2.51M | Sell |
1,254,527
-1,163,302
| -48% | -$2.33M | 0.18% | 112 |
|
|
2019
Q4 | $8.34M | Buy |
+2,417,829
| New | +$8.34M | 0.34% | 73 |
|